21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.

Abstract excerpt

PURPOSE: The 21-gene Recurrence Score (RS) assay is used to predict disease recurrence and benefit of chemotherapy in estrogen receptor-positive, lymph node-negative early-stage breast cancer (EBC). Our study is the first analysis of trends and differences in the use of the RS assay and its impact on recommending chemotherapy in a population-based data set. METHODS: Patients with EBC diagnosed from 2004 to 2012...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Neoplasms
• Share to Chemotherapy, Adjuvant